Interactive Learning: Navigating GLP-1 RA Therapy to Improve Health Outcomes in Type 2 Diabetes: Practical Considerations for Primary Care is organized by Pri-Med.
Release Date: 11/01/2024
Expiration Date: 11/01/2025
Description:
This infographic reviews the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) approved for treatment of type 2 diabetes, including their glycemic and extraglycemic effects. Clinical practice recommendations for the use of GLP-1 RAs are provided, along with top tips for initiating therapy effectively and safely in the clinic.
Learning Objectives:
Upon completion of this activity, participants will be able to:
Topics:
Accreditation Statement
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement
Pri-Med Institute is accredited by the American Association of Nurse Practitioners® as an approved provider of nurse practitioner continuing education. Provider number: 040308. This activity is approved for 0.25 contact hour(s) (which includes 0.25 hour(s) of pharmacology).
Designation Statement
This activity is approved for 0.25 contact hour, which includes 0.25 hour of pharmacology.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Copyrights © 2026 eMedEvents Corporation, All Rights Reserved